Skip to main content
PolicySpeak
← The ranking

Side by side

Compare organizations

Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.

Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

HAP
2
files engaged
of 583 tracked
2
positions filed
in those 583 files
1.5
declared FTE
self-declared
1
EP accreditations
as declared to the register

Declared costs: €100K+ a year · in the register since 2016

17
files engaged
of 583 tracked
19
positions filed
in those 583 files
4.3
declared FTE
self-declared
0
EP accreditations
as declared to the register

Declared costs: not declared · in the register since 2010

Files both filed on (2)

Medicinal products for human use · Revision of the EU legislation on medicines for children and rare diseases

Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.

What each said, in their own words

Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.

Medicinal products for human use

European Public Health Alliance (EPHA) · filed 27 Apr 2021 · source

The revision of the EU general pharmaceuticals legislation should aim to address the problems of availability, accessibility and affordability of medicines as well as to incentivise meaningful, public health needs-driven biomedical innovation. Put simply, it should serve the goal of having better and affordable medicines for those who need them.

Hellenic Association of Pharmaceutical Companies · filed 8 Nov 2023 · source

The reform of the EUs pharmaceutical sector is a milestone of the European Health Union and a credible step in our collective step to pave the way towards a healthier, more resilient, and more equal Europe.SFEE fully supports the challenges of enhancing the availability and acceptability of medicines, all fostering a competitive innovation environment in Europe.

Filed in Greek · English published by the European Commission

Revision of the EU legislation on medicines for children and rare diseases

European Public Health Alliance (EPHA) · filed 18 Dec 2020 · source

Small biotechs, university spin-offs and other research institutions are now at the heart of pharmaceutical R&D conducting the early-stage research, financed by venture capitalists, hedge funds and private equity. Large pharmaceutical companies perform less research in-house while they scan the horizon for promising products and companies. They subsequently acquire them.

Hellenic Association of Pharmaceutical Companies · filed 5 Jan 2021 · source

Hellenic Association of Pharmaceutical Companies (SFEE) members are committed to ensuring that unmet needs are addressed and that available treatments reach all European patients. Children and rare disease (RD) patients have greatly benefited from the progress achieved through the Paediatric & Orphan Regulations.

Take this comparison with you

2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.